AstraZeneca posts positive Phase III VOLGA bladder cancer data: full analysis
AstraZeneca reported positive top-line Phase III data from VOLGA on May 14, saying perioperative Imfinzi plus neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for, or declined, cisplatin-based chemotherapy. In the same announcement, the company said the triplet of Imfinzi, tremelimumab, and enfortumab vedotin improved event-free survival, but overall survival had only a favorable trend and was not statistically significant at this interim look. (investegate.co.uk)
That matters because the perioperative bladder cancer landscape has changed quickly over the past 18 months. The FDA approved durvalumab with gemcitabine and cisplatin in March 2025 for adults with muscle-invasive bladder cancer undergoing cystectomy, but that regimen is for cisplatin-eligible patients. Then, on November 21, 2025, the FDA approved pembrolizumab plus enfortumab vedotin as neoadjuvant and adjuvant therapy after cystectomy for adults with muscle-invasive bladder cancer who are ineligible for cisplatin. VOLGA gives AstraZeneca a potential route into that same cisplatin-ineligible segment, where unmet need has remained high. (fda.gov)
VOLGA itself is a global, randomized Phase III study in cisplatin-ineligible muscle-invasive bladder cancer, designed to compare perioperative durvalumab-based regimens with standard care. Trial materials show the study enrolled patients with clinical stage T2-4aN0-N1M0 disease and was expected to include roughly 830 patients, though a later AstraZeneca clinical-trial appendix listed 712 patients and projected data in the first half of 2026. AstraZeneca's topline release said the control arm received radical cystectomy with or without approved adjuvant treatment. (bladder.uroonco.uroweb.org)
The company hasn't yet released hazard ratios, absolute survival gains, or detailed safety tables from VOLGA. What it did say is that the doublet showed statistically significant and clinically meaningful gains in both event-free and overall survival, while the triplet improved event-free survival with safety consistent with known profiles. Thomas Powles, the trial's international coordinating investigator, said patients who can't receive cisplatin face high recurrence risk even after bladder removal, and described the durvalumab-plus-enfortumab vedotin regimen as having a manageable safety profile in this curative-intent setting. Because the data are still high level, the field will likely wait for a conference presentation to judge the magnitude of benefit and toxicity tradeoffs. (investegate.co.uk)
Industry context is important here. Enfortumab vedotin has become a central drug in bladder cancer across multiple settings, and competitors have already raised the bar. At the 2026 ASCO Genitourinary Cancers Symposium, KEYNOTE-B15 showed that perioperative enfortumab vedotin plus pembrolizumab improved event-free survival, overall survival, and pathologic complete response in cisplatin-eligible muscle-invasive bladder cancer. Separately, reporting on KEYNOTE-905 described perioperative enfortumab vedotin plus pembrolizumab as superior to cystectomy alone in cisplatin-ineligible or cisplatin-declining patients. In that context, VOLGA suggests AstraZeneca is not creating a new category so much as trying to secure a place in one that's already becoming highly competitive. (ascopost.com)
Why it matters: For oncology teams, the bigger story is that perioperative systemic therapy is moving deeper into earlier-stage bladder cancer, including patients once treated mainly with surgery alone because they couldn't tolerate cisplatin. That could mean more multidisciplinary coordination between medical oncology, urologic oncology, infusion services, and perioperative teams, along with closer management of immune-related adverse events, skin toxicity, neuropathy, and surgical timing. It also raises a practical question for clinicians: if multiple perioperative EV-based regimens are available or become available, treatment selection may hinge less on whether to intensify therapy and more on which combination offers the best balance of survival benefit, toxicity, logistics, and label fit for a given patient. (investegate.co.uk)
What to watch: The next milestones are a full medical-meeting presentation, regulatory submissions, and more detail on pathologic complete response, subgroup performance, and safety, especially whether the doublet can differentiate itself against the already approved pembrolizumab-enfortumab vedotin option in cisplatin-ineligible disease. (investegate.co.uk)